Phase I/II Trial of Motesanib in Combination With Ixabepilone and Capecitabine in Women With Locally Recurrent or Metastatic Breast Cancer.

Trial Profile

Phase I/II Trial of Motesanib in Combination With Ixabepilone and Capecitabine in Women With Locally Recurrent or Metastatic Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Motesanib (Primary) ; Capecitabine; Ixabepilone
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jan 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to withdrawn prior to recruitment.
    • 20 May 2013 Planned initiation date changed from 1 Sep 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top